Wolverine Stack
BPC-157 + TB-500 — Research Protocol Overview
The Wolverine Stack refers to the research combination of BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4). In preclinical models (primarily rodent, cell culture, and in vitro studies), BPC-157 is examined for localized tissue repair, tendon/ligament support, and cytoprotective effects, while TB-500 is studied for systemic cell migration, actin regulation, angiogenesis, and broader wound healing. Researchers explore them together for potential complementary mechanisms in tissue regeneration models. All peptides on this site are sold strictly for laboratory research purposes only and are not for human consumption.
Important Disclaimer: This page summarizes publicly available preclinical literature and common research protocols discussed in scientific contexts. No claims are made about human efficacy, safety, or therapeutic use. Always consult primary PubMed sources and comply with all local regulations. Long-term risks in any model remain understudied.
Mechanisms of Action (Preclinical Research)
BPC-157
Stable gastric pentadecapeptide studied for:
- • Modulating inflammatory pathways
- • Promoting tendon fibroblast proliferation
- • Collagen organization & angiogenesis
- • Cytoprotective effects in gut, tendon, muscle, and spinal cord injury models
TB-500
Synthetic Thymosin Beta-4 fragment studied for:
- • Actin sequestration & cell migration
- • Endothelial differentiation
- • Neovascularization in wound models
- • Systemic support in musculoskeletal injury models
Synergy Rationale
BPC-157 often shows stronger localized effects (e.g., near injury site), while TB-500 provides more systemic support. Researchers study the pair for additive or complementary signaling in musculoskeletal and soft tissue models.
Common Research Protocols in Literature
Aggregated from preclinical and reported research contexts (primarily animal-derived or extrapolated in lab discussions).
| Component | Common Research Dose | Frequency | Administration | Duration |
|---|---|---|---|---|
| BPC-157 | 200–500 mcg/day | Daily | Subcutaneous (near injury site); oral in gut models | 4–8 weeks |
| TB-500 | 2–5 mg (loading); 2 mg (maintenance) | 2x/week → 1x/week | Subcutaneous (systemic) | 4–8 weeks |
| Combined Stack | As above, administered separately | Per individual schedules | Separate injections or co-administered | 4–12 weeks |
Example Research Protocol Outline
Loading / Acute Phase (Weeks 1–4)
BPC-157 daily + TB-500 twice weekly.
Maintenance Phase (Weeks 5–8)
BPC-157 daily (or tapered) + TB-500 once weekly.
Cycle Length
4–8 weeks for most injury models; up to 12 weeks in chronic studies. Follow with washout period (2–4 weeks).
Reconstitution
Use bacteriostatic water. Gentle mixing to avoid degradation. Store reconstituted vials refrigerated.
Site Rotation
For subcutaneous injections, rotate sites in lab animal models.
Key Complementary Effects Studied
| Research Aspect | BPC-157 Focus | TB-500 Focus | Combined Interest |
|---|---|---|---|
| Tissue Repair | Tendon, ligament, muscle, gut mucosa | Wound healing, muscle, systemic | Musculoskeletal + broader recovery |
| Angiogenesis | Promotes in certain models | Strong endothelial migration | Enhanced vascular support |
| Inflammation | Modulates pathways | Reduces in wound models | Balanced modulation |
| Cell Migration | Tenocyte/fibroblast support | Actin-based migration | Synergistic regeneration signals |
Frequently Asked Questions
Why is it called the "Wolverine Stack"?▼
Informal nickname referencing rapid regenerative themes observed in animal literature. It is not a formal scientific term.
Can BPC-157 and TB-500 be researched together?▼
Yes. Preclinical studies and research discussions frequently reference combined use for complementary tissue repair mechanisms. BPC-157 targets localized healing while TB-500 provides systemic support.
What about oral vs injectable BPC-157?▼
BPC-157 has been researched in both forms. Oral administration is common in gut-focused models, while systemic tissue studies typically use injectable (subcutaneous) routes.
Should research protocols include cycling?▼
Common practice includes washout periods (2–4 weeks) between research cycles of 4–8 weeks. This allows for baseline return before resuming study protocols.
What purity standards should be used?▼
For reproducible results, use HPLC-verified peptides with ≥99% purity. NovaPure Labs provides third-party COAs with every order to ensure batch-specific quality validation.
Ready to Start Your Research?
All NovaPure Labs peptides include a Certificate of Analysis. Third-party lab tested, Canadian-sourced.